Some of the most talked about data at ACC.24 were the results of a late-breaking clinical trial comparing different transcatheter aortic valve replacement (TAVR) valves in patients with a small aortic annulus. 

The young patient was discharged 10 days later, and no postoperative complications have been reported.

Trainees interested in interventional cardiology will now be able to use the Match program to find the right program for their needs. The move is associated with multiple benefits as well as some key challenges.

Leadless pacemakers may be an "attractive alternative" to transvenous devices when cardiologists treat older TAVR patients who experience conduction disorders.

Inspired by nature and funded by the European Research Council, a group of scientists and engineers thinks its new research could represent a significant breakthrough in TAVR care.

Care teams are always looking for new ways to limit the use of permanent pacemakers after TAVR. Could starting patients off with temporary devices be an answer? 

Edwards, an early investor when the company first launched in 2017, said the acquisition will ensure its TMVR platform reaches as many patients as possible. 

The self-expanding valve is not yet approved by the FDA, but care teams in other markets are reporting positive outcomes when patients go home the day after treatment.